PT Journal AU Chan, C Lustig, M Baumann, N Valerius, T van Tetering, G Leusen, JHW TI Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies? SO Frontiers in immunology PY 2022 VL 13 PU Frontiers Media SA DI 10.3389/fimmu.2022.932155 WP https://macau.uni-kiel.de/receive/macau_mods_00002913 LA en DE Humans; Neoplasms; Immunoglobulin A; Immunoglobulin G; Receptors, Immunologic; Antigens, Differentiation; Phagocytosis; CD47 Antigen; Antibodies; Macrophages; IGA; Immune Checkpoint; Neutrophils (Pmns); Myeloid Checkpoints; Cd47-sirpalpha Axis; Cancer Immonotherapy SN 1664-3224 AB Immunotherapy with therapeutic antibodies has shown a lack of durable responses in some patients due to resistance mechanisms. Checkpoint molecules expressed by tumor cells have a deleterious impact on clinical responses to therapeutic antibodies. Myeloid checkpoints, which negatively regulate macrophage and neutrophil anti-tumor responses, are a novel type of checkpoint molecule. Myeloid checkpoint inhibition is currently being studied in combination with IgG-based immunotherapy. In contrast, the combination with IgA-based treatment has received minimal attention. IgA antibodies have been demonstrated to more effectively attract and activate neutrophils than their IgG counterparts. Therefore, myeloid checkpoint inhibition could be an interesting addition to IgA treatment and has the potential to significantly enhance IgA therapy. PI Lausanne ER